---
document_datetime: 2025-12-02 06:11:40
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/inpremzia.html
document_name: inpremzia.html
version: success
processing_time: 0.102067
conversion_datetime: 2025-12-27 16:02:21.407769
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Inpremzia

[RSS](/en/individual-human-medicine.xml/67563)

##### Withdrawn

This medicine's authorisation has been withdrawn

insulin human (rDNA) Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Inpremzia](#news-on)
- [Related content](#related-content-951)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 4 April 2023, the European Commission withdrew the marketing authorisation for Inpremzia (insulin human (rDNA)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Baxter Holding B.V., which notified the European Commission of its decision not to market the product in the European Union for commercial reasons.

Inpremzia was granted marketing authorisation in the EU on 25 April 2022 for treatment of patients with diabetes mellitus who require intravenous insulin.

Inpremzia is a biosimilar medicinal product. It is highly similar to the reference product Actrapid (human insulin), which is authorised in the EU to treat diabetes mellitus.

The European Public Assessment Report (EPAR) for Inpremzia is updated to indicate that the marketing authorisation is no longer valid.

Inpremzia : EPAR - Medicine overview

Reference Number: EMEA/H/C/005331

English (EN) (706.34 KB - PDF)

**First published:** 30/06/2022

**Last updated:** 20/04/2023

[View](/en/documents/overview/inpremzia-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-933)

български (BG) (766.69 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/bg/documents/overview/inpremzia-epar-medicine-overview_bg.pdf)

español (ES) (701.11 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/es/documents/overview/inpremzia-epar-medicine-overview_es.pdf)

čeština (CS) (755.81 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/cs/documents/overview/inpremzia-epar-medicine-overview_cs.pdf)

dansk (DA) (696.22 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/da/documents/overview/inpremzia-epar-medicine-overview_da.pdf)

Deutsch (DE) (699.47 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/de/documents/overview/inpremzia-epar-medicine-overview_de.pdf)

eesti keel (ET) (684.25 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/et/documents/overview/inpremzia-epar-medicine-overview_et.pdf)

ελληνικά (EL) (797.91 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/el/documents/overview/inpremzia-epar-medicine-overview_el.pdf)

français (FR) (698.83 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/fr/documents/overview/inpremzia-epar-medicine-overview_fr.pdf)

hrvatski (HR) (716.73 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/hr/documents/overview/inpremzia-epar-medicine-overview_hr.pdf)

italiano (IT) (694.38 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/it/documents/overview/inpremzia-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (758.76 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/lv/documents/overview/inpremzia-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (717.55 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/lt/documents/overview/inpremzia-epar-medicine-overview_lt.pdf)

magyar (HU) (751.39 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/hu/documents/overview/inpremzia-epar-medicine-overview_hu.pdf)

Malti (MT) (755.61 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/mt/documents/overview/inpremzia-epar-medicine-overview_mt.pdf)

Nederlands (NL) (701.08 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/nl/documents/overview/inpremzia-epar-medicine-overview_nl.pdf)

polski (PL) (755.89 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/pl/documents/overview/inpremzia-epar-medicine-overview_pl.pdf)

português (PT) (699.33 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/pt/documents/overview/inpremzia-epar-medicine-overview_pt.pdf)

română (RO) (716.07 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/ro/documents/overview/inpremzia-epar-medicine-overview_ro.pdf)

slovenčina (SK) (751.22 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/sk/documents/overview/inpremzia-epar-medicine-overview_sk.pdf)

slovenščina (SL) (747.71 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/sl/documents/overview/inpremzia-epar-medicine-overview_sl.pdf)

Suomi (FI) (694.89 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/fi/documents/overview/inpremzia-epar-medicine-overview_fi.pdf)

svenska (SV) (695.38 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/sv/documents/overview/inpremzia-epar-medicine-overview_sv.pdf)

Inpremzia : EPAR - Risk management plan summary

English (EN) (718.91 KB - PDF)

**First published:** 30/06/2022

**Last updated:** 20/04/2023

[View](/en/documents/rmp-summary/inpremzia-epar-risk-management-plan-summary_en.pdf)

## Product information

Inpremzia : EPAR - Product Information

English (EN) (1.03 MB - PDF)

**First published:** 30/06/2022

**Last updated:** 20/04/2023

[View](/en/documents/product-information/inpremzia-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-554)

български (BG) (1.81 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/bg/documents/product-information/inpremzia-epar-product-information_bg.pdf)

español (ES) (1.04 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/es/documents/product-information/inpremzia-epar-product-information_es.pdf)

čeština (CS) (1.54 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/cs/documents/product-information/inpremzia-epar-product-information_cs.pdf)

dansk (DA) (1.01 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/da/documents/product-information/inpremzia-epar-product-information_da.pdf)

Deutsch (DE) (1.05 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/de/documents/product-information/inpremzia-epar-product-information_de.pdf)

eesti keel (ET) (1.01 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/et/documents/product-information/inpremzia-epar-product-information_et.pdf)

ελληνικά (EL) (1.85 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/el/documents/product-information/inpremzia-epar-product-information_el.pdf)

français (FR) (1.03 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/fr/documents/product-information/inpremzia-epar-product-information_fr.pdf)

hrvatski (HR) (1.06 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/hr/documents/product-information/inpremzia-epar-product-information_hr.pdf)

íslenska (IS) (1.02 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/is/documents/product-information/inpremzia-epar-product-information_is.pdf)

italiano (IT) (1.04 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/it/documents/product-information/inpremzia-epar-product-information_it.pdf)

latviešu valoda (LV) (1.57 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/lv/documents/product-information/inpremzia-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.08 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/lt/documents/product-information/inpremzia-epar-product-information_lt.pdf)

magyar (HU) (1.58 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/hu/documents/product-information/inpremzia-epar-product-information_hu.pdf)

Malti (MT) (1.61 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/mt/documents/product-information/inpremzia-epar-product-information_mt.pdf)

Nederlands (NL) (1.05 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/nl/documents/product-information/inpremzia-epar-product-information_nl.pdf)

norsk (NO) (1.02 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/no/documents/product-information/inpremzia-epar-product-information_no.pdf)

polski (PL) (1.57 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/pl/documents/product-information/inpremzia-epar-product-information_pl.pdf)

português (PT) (1.02 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/pt/documents/product-information/inpremzia-epar-product-information_pt.pdf)

română (RO) (1.1 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/ro/documents/product-information/inpremzia-epar-product-information_ro.pdf)

slovenčina (SK) (1.56 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/sk/documents/product-information/inpremzia-epar-product-information_sk.pdf)

slovenščina (SL) (1.56 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/sl/documents/product-information/inpremzia-epar-product-information_sl.pdf)

Suomi (FI) (1.02 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/fi/documents/product-information/inpremzia-epar-product-information_fi.pdf)

svenska (SV) (1.02 MB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/sv/documents/product-information/inpremzia-epar-product-information_sv.pdf)

04/04/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Inpremzia : EPAR - All Authorised Presentations

English (EN) (616.14 KB - PDF)

**First published:** 30/06/2022

**Last updated:** 20/04/2023

[View](/en/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-719)

български (BG) (641.03 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/bg/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_bg.pdf)

español (ES) (611.68 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/es/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_es.pdf)

čeština (CS) (630.55 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/cs/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (617.03 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/da/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (613.74 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/de/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (609.79 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/et/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (639.06 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/el/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_el.pdf)

français (FR) (615.53 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/fr/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (612.8 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/hr/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (613.28 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/is/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_is.pdf)

italiano (IT) (610.05 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/it/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (632.83 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/lv/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (614.3 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/lt/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (628.54 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/hu/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (632.3 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/mt/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (610.3 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/nl/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (613.53 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/no/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_no.pdf)

polski (PL) (631.12 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/pl/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_pl.pdf)

português (PT) (611.83 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/pt/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_pt.pdf)

română (RO) (614.43 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/ro/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (634.14 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/sk/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (628.79 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/sl/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (608.23 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/fi/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (611.32 KB - PDF)

**First published:**

30/06/2022

**Last updated:**

20/04/2023

[View](/sv/documents/all-authorised-presentations/inpremzia-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Inpremzia Active substance insulin human (rDNA) International non-proprietary name (INN) or common name insulin human (rDNA) Therapeutic area (MeSH) Diabetes Mellitus Anatomical therapeutic chemical (ATC) code A10AB01

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Inpremzia is indicated for the treatment of diabetes mellitus.

## Authorisation details

EMA product number EMEA/H/C/005331

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Baxter Holding B.V.

Kobaltweg 49 3542 CE Utrecht Netherlands

Opinion adopted 24/02/2022 Marketing authorisation issued 25/04/2022

## Assessment history

## Initial marketing authorisation documents

Inpremzia : EPAR - Public Assessment Report

Reference Number: EMA/127616/2022

English (EN) (2.32 MB - PDF)

**First published:** 30/06/2022

**Last updated:** 20/04/2023

[View](/en/documents/assessment-report/inpremzia-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Inpremzia

Adopted

Reference Number: EMA/CHMP/113249/2022

English (EN) (702.86 KB - PDF)

**First published:** 25/02/2022

**Last updated:** 20/04/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-inpremzia_en.pdf)

#### News on Inpremzia

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022) 25/02/2022

#### Related content

- [Biosimilar medicines: Overview](/en/human-regulatory-overview/biosimilar-medicines-overview)

**This page was last updated on** 20/04/2023

## Share this page

[Back to top](#main-content)